1. Home
  2. Browse
  3. HRA003368
HRA003368
   HRA003368.xlsx
Title:
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Release date:
2023-03-01
Description:
We applied four well-established circRNA identification tools to characterize the circRNA expression profiles of two independent cohorts of 157 ICB-treated patients with advanced melanoma. We observed overall overexpression of circRNAs in ICB non-responders as compared with responders in both pre-treatment biopsies (PRE) and early during therapy (EDT). We then constructed circRNA-miRNA-mRNA regulatory networks and revealed circRNA-related signaling pathways in the context of ICB treatment. Furthermore, we employed a machine learning approach to identify a novel ICB-related circRNA signature (ICBcircSig) based on progression-free survival-related circRNAs. This ICBcircSig was able to accurately predict the therapeutic efficacy of ICB in three independent patient cohorts and outperforms predictions made based on the expression of PD-L1 and the 20 transcriptome-based features.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA012879
Study type:
Disease Study
Disease name:
Melanoma
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC001921
DAC name:
Total RNA-seq
Contact person:
Liu Hong
Email:
hongliu1014@csu.edu.cn
Description:
The cohort of 24 patients with melanoma evaluated in this study received anti-PD-1 treatment or a combination of anti-PD-1 and anti-CTLA-4 collected from Fudan University Shanghai Cancer Centre and Xiangya Hospital between May 2018 and September 2020.
Individuals & samples
Files
Request Data
Submitter:   Liu Hong / hongliu1014@csu.edu.cn
Organization:   Central South University
Submission date:   2022-07-29
Requests:   -